A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial

Publikation: Bidrag til tidsskriftLetterForskningfagfællebedømt


  • Fulltext

    Forlagets udgivne version, 443 KB, PDF-dokument

  • Mona Bafadhel
  • Neil Barnes
  • Stephen C. Bourke
  • Chris Compton
  • Gerard J. Criner
  • Mark T. Dransfield
  • David M.G. Halpin
  • Mei Lan K. Han
  • Benjamin Hartley
  • C. Elaine Jones
  • Lange, Peter
  • Sally Lettis
  • David A. Lipson
  • David A. Lomas
  • Neil Martin
  • Fernando J. Martinez
  • Robert Wise
  • Dave Singh
TidsskriftEuropean Respiratory Journal
Udgave nummer3
Antal sider5
StatusUdgivet - 2021

Bibliografisk note

Funding Information:
Conflict of interest: M. Bafadhel reports grants from AstraZeneca; advisory board attendance for AstraZeneca, Chiesi, Boehringer Ingelheim and GSK (in the last 3 years); attendance at educational meetings facilitated by AstraZeneca, Chiesi and Boehringer Ingelheim (in the last 3 years); and scientific advisor for ProAxsis and AlbusHealth. N. Barnes is an employee of GSK and holds stocks and shares in GSK. S.C. Bourke reports research grants from GSK, Philips, ResMed and Pfizer Open Air, support to attend scientific meetings from Boehringer Ingelheim, Chiesi, GSK and AstraZeneca and personal fees from Novartis, Chiesi and ResMed. C. Compton is an employee of GSK and holds stocks and shares in GSK. G.J. Criner reports personal fees from Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Broncus Medical, Chiesi, CSA Medical, Eolo, Gala Therapeutics, GSK, Helios Medical, Medtronic, Merck, Mereo BioPharma, NGM Pharmaceuticals, Novartis, Nuvaira, Olympus, Philips Respironics, Pulmonx, Respivant Sciences, The Implementation Group and Verona; and has ownership interest in HGE Technologies. M.T. Dransfield reports personal fees from AstraZeneca, Boehringer Ingelheim, PneumRx/BTG, Quark Pharmaceuticals and GSK, grant support from the American Lung Association, Department of Defense, Department of Veterans Affairs and NIH, and contracted clinical trial support from Boehringer Ingelheim, Novartis, AstraZeneca, Yungjin, PneumRx/BTG, Pulmonx, Boston Scientific, Gala, Nuvaira and GSK. D.M.G. Halpin reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Pfizer and Sanofi, and non-financial support from Boehringer Ingelheim and Novartis. M.K. Han reports personal fees from AstraZeneca, GSK, Mylan, Merck and Boehringer Ingelheim, and research support from Novartis and Sunovion. B. Hartley is a contingent worker with a contract research organisation working on behalf of GSK and holds shares in GSK. C.E. Jones is an employee of GSK and holds stocks and shares in GSK. P. Lange reports personal fees from GSK, AstraZeneca and Boehringer Ingelheim, and grant support from Boehringer Ingelheim and GSK. S. Lettis is an employee of GSK and holds stocks and shares in GSK. D.A. Lipson is an employee of GSK and holds stocks and shares in GSK. D.A. Lomas reports grant income, honoraria, and consultancy fees from GSK, and personal fees from Grifols, and chaired the GSK Respiratory Therapy Area Board 2012–2015. N. Martin is an employee of GSK and holds stocks and shares in GSK. F.J. Martinez reports personal fees and non-financial support from the American College of Chest Physicians, AstraZeneca, Boehringer Ingelheim, Continuing Education, ConCert, Genentech, GSK, Inova Fairfax Health System, Miller Communications, National Society for Continuing Education, Novartis, Pearl Pharmaceuticals, PeerView Communications, Prime Communications, Puerto Rico Respiratory Society, Chiesi, Roche, Sunovion, Theravance, Potomac, University of Alabama Birmingham, Physicians Education Resource, Canadian Respiratory Network and Teva, non-financial support from ProterrixBio, Gilead, Nitto and Zambon, and personal fees from Columbia University, Integritas, MD Magazine, Methodist Hospital Brooklyn, New York University, Unity, UpToDate, WedMD/MedScape, Western Connecticut Health Network, Academic CME, Patara, PlatformIQ, American Thoracic Society, Rockpointe and France Foundation, grant support from NIH, Rare Disease Health Communications and ProMedior, and is a member of steering committees for Afferent/Merck, Biogen, Veracyte, Prometic, Bayer and Bridge Biotherapeutics. R. Wise reports personal fees from AstraZeneca/ MedImmune, Boehringer Ingelheim, ContraFect, Pulmonx, Roche, Spiration, Sunovion, Merck, Circassia, Pneuma, Verona, Bonti, Denali, Aradigm, Mylan/Theravance, Propeller Health, AbbVie and GSK, and grant support from AstraZeneca/MedImmune, Boehringer Ingelheim, Pearl Therapeutics, GSK and Sanofi-Aventis. D. Singh reports personal fees from GSK, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, Glenmark, Menarini, Mundipharma, Novartis, Peptinnovate, Pfizer, Pulmatrix, Theravance and Verona, and grant support from AstraZeneca, Boehringer Ingelheim, Chiesi, Glenmark, Menarini, Mundipharma, Novartis, Pfizer, Pulmatrix, Theravance and Verona.

Funding Information:
Acknowledgements: Editorial support (in the form of writing assistance, assembling figures, collating author comments, grammatical editing and referencing) was provided by Eloise Morecroft and Katie Baker, at Fishawack Indicia Ltd, UK, and was funded by GSK. D. Singh is supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). D.A. Lomas is supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC) and is an NIHR Senior Investigator.

Funding Information:
Support statement: This study was funded by GlaxoSmithKline (GSK; CTT116855; Clinicaltrials.gov identifier: NCT02164513). Funding information for this article has been deposited with the Crossref Funder Registry.

ID: 286926152